相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians
Daniel Geh et al.
HEPATOBILIARY SURGERY AND NUTRITION (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
Michael Dudek et al.
NATURE (2021)
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
Changhoon Yoo et al.
LIVER CANCER (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade
Tomoko Aoki et al.
CANCERS (2020)
Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review
Yuichiro Eguchi et al.
JGH OPEN (2020)
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
Atsushi Hiraoka et al.
LIVER CANCER (2019)
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease
Ankur Srivastava et al.
JOURNAL OF HEPATOLOGY (2019)
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update
Ryosuke Tateishi et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2017)
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
Atsushi Hiraoka et al.
LIVER CANCER (2017)
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
Atsushi Hiraoka et al.
LIVER CANCER (2017)
Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: Report of the Committee on Causes of Death in Diabetes Mellitus
Jiro Nakamura et al.
JOURNAL OF DIABETES INVESTIGATION (2017)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma
Atsushi Hiraoka et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong et al.
GASTROENTEROLOGY (2015)
Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study
Ryosuke Tateishi et al.
JOURNAL OF GASTROENTEROLOGY (2015)
EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease
JOURNAL OF HEPATOLOGY (2015)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Epidemiology of Hepatocellular Carcinoma Consider the Population
Sahil Mittal et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Naga Chalasani et al.
GASTROENTEROLOGY (2012)
New contrast enhanced ultrasonography agent: Impact of Sonazoid on radiofrequency ablation
Atsushi Hiraoka et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid-enhanced MR Imaging
Katsuhiro Sano et al.
RADIOLOGY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma
Amelia J. Hessheimer et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
Intraindividual Comparison of Gadoxetate Disodium-enhanced MR Imaging and 64-Section Multidetector CT in the Detection of Hepatocellular Carcinoma in Patients with Cirrhosis
Michele Di Martino et al.
RADIOLOGY (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid
Atsushi Hiraoka et al.
ONCOLOGY LETTERS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
分享论文
